Design, synthesis, and biological evaluation of 1-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-3-phenylurea derivatives as anticancer agents
Abstract A novel series of 1-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-3-phenylurea derivatives (5a–l) were designed and synthesized as sorafenib analogs. The in vitro cytotoxicity effects of synthesized compounds were evaluated against four different human cancer cells including MCF-7, HepG2, A549, and HeLa cell lines. The biological results showed that most of the compounds significantly prevented the proliferation of tested cancer cells. In particular, 2-F, 4-Cl, and 2,6-diF substituted derivatives (5d, 5g, and 5k) showed promising activities, especially against Hela cancer cells ($ IC_{50} $ = 0.37, 0.73 and 0.95 µM, respectively) which were significantly more potent than sorafenib as the reference drug ($ IC_{50} $ = 7.91 µM). Flow cytometry analysis revealed that the prototype compounds (5d, 5g, and 5k) significantly induced apoptotic cell death in HeLa cancer cells and blocked the cell cycle at the sub-G1 phase. Moreover, in silico docking study confirmed the binding of the prototype compound to the active site of VEGFR-2..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
Medicinal chemistry research - 29(2020), 11 vom: 24. Aug., Seite 2000-2010 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Aghcheli, Ayoub [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
doi: |
10.1007/s00044-020-02616-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR040997820 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR040997820 | ||
003 | DE-627 | ||
005 | 20230519164523.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00044-020-02616-2 |2 doi | |
035 | |a (DE-627)SPR040997820 | ||
035 | |a (SPR)s00044-020-02616-2-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 540 |a 610 |q ASE |
084 | |a 44.42 |2 bkl | ||
084 | |a 42.13 |2 bkl | ||
084 | |a 35.71 |2 bkl | ||
100 | 1 | |a Aghcheli, Ayoub |e verfasserin |4 aut | |
245 | 1 | 0 | |a Design, synthesis, and biological evaluation of 1-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-3-phenylurea derivatives as anticancer agents |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract A novel series of 1-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-3-phenylurea derivatives (5a–l) were designed and synthesized as sorafenib analogs. The in vitro cytotoxicity effects of synthesized compounds were evaluated against four different human cancer cells including MCF-7, HepG2, A549, and HeLa cell lines. The biological results showed that most of the compounds significantly prevented the proliferation of tested cancer cells. In particular, 2-F, 4-Cl, and 2,6-diF substituted derivatives (5d, 5g, and 5k) showed promising activities, especially against Hela cancer cells ($ IC_{50} $ = 0.37, 0.73 and 0.95 µM, respectively) which were significantly more potent than sorafenib as the reference drug ($ IC_{50} $ = 7.91 µM). Flow cytometry analysis revealed that the prototype compounds (5d, 5g, and 5k) significantly induced apoptotic cell death in HeLa cancer cells and blocked the cell cycle at the sub-G1 phase. Moreover, in silico docking study confirmed the binding of the prototype compound to the active site of VEGFR-2. | ||
650 | 4 | |a 1,3,4-Thiadiazole |7 (dpeaa)DE-He213 | |
650 | 4 | |a Anticancer |7 (dpeaa)DE-He213 | |
650 | 4 | |a Sorafenib |7 (dpeaa)DE-He213 | |
650 | 4 | |a Cytotoxic activity |7 (dpeaa)DE-He213 | |
700 | 1 | |a Toolabi, Mahsa |e verfasserin |4 aut | |
700 | 1 | |a Ayati, Adileh |e verfasserin |4 aut | |
700 | 1 | |a Moghimi, Setareh |e verfasserin |4 aut | |
700 | 1 | |a Firoozpour, Loghman |e verfasserin |4 aut | |
700 | 1 | |a Bakhshaiesh, Tayebeh Oghabi |e verfasserin |4 aut | |
700 | 1 | |a Nazeri, Elahe |e verfasserin |4 aut | |
700 | 1 | |a Norouzbahari, Maryam |e verfasserin |4 aut | |
700 | 1 | |a Esmaeili, Rezvan |e verfasserin |4 aut | |
700 | 1 | |a Foroumadi, Alireza |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medicinal chemistry research |d Cambridge, Mass. [u.a.] : Birkhäuser Boston, 1991 |g 29(2020), 11 vom: 24. Aug., Seite 2000-2010 |w (DE-627)SPR000381640 |w (DE-600)2191978-1 |x 1554-8120 |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:2020 |g number:11 |g day:24 |g month:08 |g pages:2000-2010 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00044-020-02616-2 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
912 | |a SSG-OPC-ASE | ||
936 | b | k | |a 44.42 |q ASE |
936 | b | k | |a 42.13 |q ASE |
936 | b | k | |a 35.71 |q ASE |
951 | |a AR | ||
952 | |d 29 |j 2020 |e 11 |b 24 |c 08 |h 2000-2010 |